Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    16264058 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City
Condition: Chronic Respiratory Diseases
Interventions: Other: Questionnaire;   Device: Lung function test
2 Not yet recruiting The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
Conditions: Chronic Obstructive Pulmonary Disease (COPD);   Emphysema;   Chronic Bronchitis
Intervention:
3 Not yet recruiting Changes in the Lung Clearance Index in Pediatric Patients With Asthma
Condition: Childhood Asthma
Interventions: Drug: Inhaled Fluticasone 50 mcg/twice day;   Drug: Inhaled Fluticasone 100 mcg/twice day;   Drug: Inhaled Albuterol
4 Completed Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
Condition: Asthma
Interventions: Drug: A006 DPI;   Other: Placebo DPI;   Drug: Proventil® MDI
5 Completed Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
Conditions: Asthma;   Bronchospasm;   Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Albuterol Inhalation Powder;   Drug: Placebo Control;   Drug: Active Comparator
6 Completed Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
Conditions: Cystic Fibrosis;   Pancreatic Insufficiency
Interventions: Drug: PANCRECARB® (pancrelipase);   Drug: Placebo

Indicates status has not been verified in more than two years